4.1.2. Part 2 Inclusion Criteria 1.Histological or cy tological diagnosis of locally advanced or metastatic NSCL C (squamous or non -squamous histology ) meeting the following criteria: a.Receipt of at least 1, but not more than 2, prior treatment regimens in the advanced disease setting. I n addition to participants with established metastatic or recurrent disease, the advanced disease setting also includes participants with platinum -based adjuvant, neoadjuvant, or definitive chemoradiation therapy given for locally advanced disease followed b y recurrent or metastatic disease within 6 months of completing therap y. PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 66b. Prior treatment must have included an anti- PD-1/PD -L1 and a platinum -based chemotherap y, which may have been given in combination, or sequentially; c.Prior treatment must have included an appropriate TKI if activating mutations are present, eg, EGFR/ALK/ROS1/BRAF/RET/TRK; d.Most recent treatment must have included anti -PD-1/PD -L1 for at least 4 months, without radiographic disease progression, followed by confirmed radiographic disease progression on or within 12 weeks of the last dose; e.No more than 1 prior anti -PD-1/PD -L1 treatment regimen may have been given; f.Prior anti -PD-1/PD -L1 may not have been discontinued permanently for toxicity . g.No prior treatment may have been given with any immunologic therap y other than anti PD -1 or PD -L1. 2.A mandatory archived formalinfixed paraffin embedded (FFPE) tumor tissue block (preferred) must be pr ovided. If an FFPE tumor tissue block cannot be provided, sites should contact sponsor for approval to submit slides. If an archived FFPE tissue is not available, a de novo (ie, fresh) tumor sample can substitute and should be obtained in accordance with local institutional practice for tumor biopsies. 3.Females and/or male participants age 18 years. 4.Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. 5.Measurable disease as per RECI ST v. 1.1. 6.Adequate Bone Marrow Function, including : a.Absolute Neutrophil Count (ANC) 1,500/mm3or 1.5 x 109/L; b.Platelets 100,000/mm3or 100 x 109/L; c.Hemoglobin  9 g/dL. 7.Adequate Renal Function, including: a.Estimated creatinine clearance 60 mL/min as calculated using the method standard for the institu tion. I n unequivocal cases, a 24 hour urine can be collected and used to estimate the creatinine clearance more accuratel y. 8.Adequate Liver Function, including: a.Total serum bilirubin  1.5 x ULN unless the participant has documented Gilbert syndrome; PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 67b.Aspartate and Alanine aminotransferase (AST and AL T) 2.5 x UL N; 5.0 x ULN if there is liver involvement b y the tumor; c.Alkaline phosphatase 2.5 x ULN ( 5 x UL N in case of bone metastasis). 9.Resolved acute effects of any prior therapy to baseline severit yor National Cancer Institute (NCI) CTCAE V5.0 Grade 1 except for adverse events (AEs) not constituting a safety risk by investigator judgment. Participan ts with hy pothy roidism or hy popituitarism resulting from immunotherapy who are stable on chronic horm one replacement therap y are eligibile, as are participants with adrenal insufficiency receiving doses <15mg/day or prednisone. 10. Serum or urine pregnancy test (for females of childbearing potential) negative at screening. 11.Female participants of nonchildbearing potential must meet at least 1 of the following criteria: Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state; Have undergone a documented hy sterectomy and/or bilateral oophorectomy ; Have medically confirmed ovarian failure. All other female participants (including female participants with tubal ligations) are considered to be of childbearing potential. 12.Evidence of a personally signed and dated informed consent document indicating that the participant or a legally acceptable representative has been informed of all pertinent aspects of the stud y]. 13.Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other procedures. 4.2. Part 1 Exclusion Criteria Participants, for each assigned part, with an y of the following characteristics/condi tions will not be included in the study : 4.2.1. Part 1 Exclusion Criteria 1.Participants with known sy mptomatic brain metastases, with the following two exceptions: PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 68a.Participants with previously diagnosed brain metastases are eligible if they have completed their tr eatment and have recovered from the acute effects of radiation therap y or surgery prior to study entry, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable for 3months (confirmed b y MRI ) b.Parti cipants with newly diagnosed brain metastases identified by a screening brain MRI who are clinically asymptomatic are eligible if the Investigator deems their clinical status acceptable for participation in the trial and all other inclusion and exclusion c riteria are satisfied, including being neurologically stable for 3 months since the screening brain MRI . A baseline MRI at screening is to be conducted only if clinicall y indicated based on the treating Investigator’s judgement 2.History of prior malignanc y other than the disease under stud y within the past 3 years excluding successfully resected treated basal cell carcinoma or squamous cell carcinoma of the skin or adequatel y treated carcinoma in situ. 3.Participants with intolerance to or who have had (Grade 3) allergic or anaphy lactic reaction to antibodies or infused therapeutic proteins. 4.Major surgery within 4 weeks prior to study entry . 5.Radiation therap y within 4 weeks prior to stud y entry. 6.Systemic anticancer therapy within 4 weeks prior to study entry . 7. Participant has AE(s) due to cancer therapeutics administered >4 weeks earlier, which have not recovered to CTCAE Grade 1(except alopecia, and except for AEs not constituting a safety risk by investigator judgment). 8.Active and clinicall y significa nt bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)related illness. HIV seropositive participants, who are health y and low-risk for AIDS -related outcomes,143may qualify for inclusion in the study after discussion with the Sponsor. The following criteria for immune s tatus and HIV ongoing therap y must be met for a HIV seropositive participant to be eligible for the study : a.Immune status criteria: CD4+T-cell counts ≥350 cells/ μL at the stud y start; No history of AIDS- defining opportunistic infections; PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 69Only remote AIDS-defining opportunistic infections in the past and none in one y ear prior to study start. b.Ongoing HIV therap y criteria: Must be receiving recommended concurrent ART treatment according to NIH guidelines;144 Began ART treatment >4 weeks prior to stud y start (to ensure ART is tolerated and toxicities are not confused with study drug toxicities); HIV viral load < 400 copies/mL for >4 weeks prior to st udy start (to ensure ART is tolerated and HIV controlled). Anti- retroviral medications should be listed as concomitant medication. Equivocal cases of viral hepatitis may be eligible if they have a negative viral load. 9.Receipt of an immunosuppressive dose of corticosteroids (ie, 10 mg prednisone daily or equivalent) or other immunosuppressive medication (eg, methotrexate, rapam ycin) within 2 weeks of registration. Note: Participants with adrenal insufficiency may take 5 mg of prednisone or equivalent daily . Topical applications, inhaled spray s, eye drops or local injections of corticosteroids are allowed. Low dose corticosteroids for a short duration [5 mg once daily (QD) prednisone for 2 weeks] as sy mptomatic treatment and upon with discussion with the sponsor is allowed. 10.History of or active autoimmune disorders (including but not limited to: my asthenia gravis, thy roiditis, pneumonitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, scleroderma) and other conditions that di sorganize or alter the immune system. Active inflammatory gastrointestinal disease, Crohn’s disease, ulcerative colitis, and primary sclerosing cholangitis are excluded, however, gastroesophageal reflux disease under treatment with protonpump inhibitors i s allowed (assuming no drug interaction potential). 11.Acet ylcholine receptor binding antibod y ≥0.5 nmol/L . 12.Abnormal neurologic examination at screening indicating possible underly ing autoimmune disorder(s). 13.Any of the following in the previous 12 months or currentl y: myocardial infarction, severe/unstable angina, coronary /peripheral artery by pass graft, s ymptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism, as well as ongoing cardiac d ysrhythmias of NCI CTCAE Grade 2, atrial fibrillation or any grade, or QTc interval >470 msec at screening. PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 7014. Individuals in whom a skin- fold measurement of the cutaneous and subcutaneous tissue for two or more eligible injection sites exceeds 50 millimeters ( mm). 15. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate IM injection. 16.Current use of an y implanted electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators. 17.Presence of an y surgical or traumatic metal implants at the site of administration (medial deltoid muscles or overl ying skin or vastus lateralis muscle). 18.Hypertension that cannot be controlled by medications ( >150/100 mmHg despite optimal medical therap y).